Research & Innovation - Participant Portal

Personalising health and care

H2020-PHC-2014-two-stageSub call of: H2020-PHC-2014-2015
Planned Opening date 11-12-2013
Publication date 11-12-2013 Deadline Date 11-03-2014 17:00:00 (Brussels local time)
Stage 2 19-08-2014 17:00:00 (Brussels local time)
Total Call Budget €303,000,000 Main Pillar Societal Challenges
Status Closed OJ reference OJ C 361 of 11 December 2013
Topic: New therapies for chronic non-communicable diseases

Specific challenge: Chronic non-communicable diseases represent a significant burden on individuals and healthcare systems. Innovative, cost effective therapeutic approaches are required to provide the best quality of care when prevention fails. While a considerable amount of knowledge has been generated by biomedical research in recent years, the development of new therapies is stagnating, in part due to a lack of clinical validation.

Scope: Clinical trial(s) supporting proof of concept in humans to assess the potential clinical efficacy of the novel therapeutic concept(s) and / or optimisation of available therapies (e.g. drug repurposing). The application may build on pre-existing pre-clinical research and additional results from large scale databases. A concise feasibility assessment justified by available published and preliminary results and supporting data should also be provided. Considerations of effectiveness and potential clinical benefit (possibly including real world data) should be integrated in the application if relevant.        

The Commission considers that proposals requesting a contribution from the EU of between EUR 4 and 6 million would allow this specific challenge to be addressed appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts.


Expected impact: This should provide:

·         New therapeutic strategies, adapted where relevant to the differing needs of men and women, with the highest potential to generate advances in clinical practice for chronic diseases, including multi- or comorbidity, ready for further development.

·         Early exclusion of candidate strategies unlikely to succeed.

·         Contribute to the improvement of the therapeutic outcome of major chronic health issues with significant impact on burden of diseases both for individual patients and for health care systems.     

Type of action: Research and innovation actions

Please read carefully all provisions below before the preparation of your application.

  1. List of countries and applicable rules for funding: described in part A of the General Annexes of the General Work Programme.
  2. Eligibility and admissibility conditions: described in part B and C of the General Annexes of the General Work Programme
  3. Evaluation

    3.1  Evaluation criteria and procedure, scoring and threshold: described in part H of the General Annexes of the General Work Programme, with the following exceptions
    The thresholds for each criterion at stage 1 (of a two stage process) will be 4 and 4. The cumulative threshold will be 8.
    The thresholds for each criterion at stage 2 (of a two stage process) will be 4, 4 and 3. The cumulative threshold will be 12.
    If a proposal fails to achieve the threshold for a criterion at any stage, the evaluation of the proposal will be stopped.
    The median of individual evaluator scores may be used at stage 1 to determine the consensus score and when appropriate, the resulting consensus report may comprise elements of these individual reports, or standard phrases representative thereof.
    The page limit for stage 1 proposals is 7 pages (including the title page).

    3.2 Guide to the submission and evaluation process
  4. Proposal page limits and layout: Please refer to Part B of the standard proposal template.
  5. Indicative timetable for evaluation and grant agreement:
    Information on the outcome of two-stage evaluation: maximum 5 months from the final date for submission.
    Signature of grant agreements: maximum 3 months from the date of informing successful applicants.
  6. Provisions, proposal templates and evaluation forms for the type(s) of action(s) under this topic:

    Research and Innovation Action:

    Specific provisions and funding rates
    Annotated Model Grant Agreement

    pdf templates for part B of the proposal (called technical annex) and an evaluation form for this call are available under on the call page under “call documents”. If you want the Technical Annex template in word format you need to register for submission and download it from the system.
    In addition, on the same page a specific template for essential information for clinical trials/studies/investigations Applicants are requested to consult the information for clinical trials at stage one even though it has to be completed only at stage 2 and to be uploaded under call specific questions in the table of contents.
  7. Additional provisions:

    Horizon 2020 budget flexibility

    Classified information
  8. Open access must be granted to all scientific publications resulting from Horizon 2020 actions, and proposals must refer to measures envisaged. Where relevant, proposals should also provide information on how the participants will manage the research data generated and/or collected during the project, such as details on what types of data the project will generate, whether and how this data will be exploited or made accessible for verification and re-use, and how it will be curated and preserved.


Additional documents

You can download the same documents as one zip file from the call page

  • Legal basis - Specific Programme H2020 en
  • WP H2020 - 1. Introduction en
  • WP H2020 - draft corrigendum en
  • WP H2020 - 8. Health, demographic change and wellbeing en
  • Legal basis - Framework Programme H2020 en
  • Legal basis - Rules for Participation en
  • WP H2020 - 19. General Annexes en
  • FAQ en
  • Self Evaluation form en
  • Essential information for clinical studies en
  • Part B Proposal template section 1-5 - updated 14_01_2014 en

No submission system is open for this topic.